N. Watanabe

Adoptive cell therapy using tumor‐infiltrating lymphocytes for melanoma refractory to immune‐checkpoint inhibitors

S. Ohta, M. Amagai, Y. Kawakami, 2021, Cancer science.

Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients

H. Nakauchi, E. Ito, S. Yuasa, 2014, Leukemia.

Production and nonclinical evaluation of an autologous iPSC–derived platelet product for the iPLAT1 clinical trial

J. Kanda, A. Sawaguchi, A. Takaori-Kondo, 2022, Blood advances.

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia.

D. Tenen, H. Koeffler, D. Perrotti, 2003, Blood.

Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele

S. Miyano, Y. Shiraishi, K. Chiba, 2016, Blood Cancer Journal.

iPLAT1: The first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study.

J. Kanda, H. Hirai, M. Minami, 2022, Blood.

Title Genetic basis of myeloid transformation in familial platelet disorder / acute myeloid leukemia patients with haploinsufficient RUNX 1 allele

S. Miyano, Y. Shiraishi, K. Chiba, 2019 .